Cangene gets FDA approval for HepaGam B for hepatitis B

New York, Jan. 30 - Cangene said the Food and Drug Administration approved its HepaGam B for treatment following acute exposure to hepatitis B virus.

HepaGam B is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus. Hepatitis B is a highly infectious virus that can be spread through contact with blood and other bodily fluids from an infected person or can be transmitted from an infected mother to a newborn during birth.

Cangene expects the drug will be launched in the next few months and to be distributed in the United States by Apotex Corp., a member of the Apotex Group, Cangene's majority shareholder.

"This is Cangene's fourth approved drug and the third drug to receive FDA approval - a significant accomplishment for a biopharmaceutical company. The depth of our hyperimmune program keeps growing, as does our international reputation," said John Langstaff, Cangene's president and chief executive officer, in a news release.

Cangene is a Winnipeg, Manitoba-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.